189 related articles for article (PubMed ID: 15705889)
1. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer.
De Maria R; Olivero M; Iussich S; Nakaichi M; Murata T; Biolatti B; Di Renzo MF
Cancer Res; 2005 Feb; 65(3):907-12. PubMed ID: 15705889
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
3. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
4. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
5. HER2 regulatory control of angiopoietin-2 in breast cancer.
Carter WB; Ward MD
Surgery; 2000 Aug; 128(2):153-8. PubMed ID: 10922985
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
Niu G; Carter WB
Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
[TBL] [Abstract][Full Text] [Related]
7. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.
Lattrich C; Juhasz-Boess I; Ortmann O; Treeck O
Oncol Rep; 2008 Mar; 19(3):811-7. PubMed ID: 18288420
[TBL] [Abstract][Full Text] [Related]
8. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
9. A new cis element is involved in the HER2 gene overexpression in human breast cancer cells.
Grooteclaes M; Vernimmen D; Plaza S; Pasleau F; Hodzic D; Winkler-Gol R
Cancer Res; 1999 Jun; 59(11):2527-31. PubMed ID: 10363966
[TBL] [Abstract][Full Text] [Related]
10. Biologic and therapeutic role of HER2 in cancer.
Ménard S; Pupa SM; Campiglio M; Tagliabue E
Oncogene; 2003 Sep; 22(42):6570-8. PubMed ID: 14528282
[TBL] [Abstract][Full Text] [Related]
11. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
Vazquez-Martin A; Colomer R; Menendez JA
Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
[TBL] [Abstract][Full Text] [Related]
12. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours.
Maniscalco L; Iussich S; de Las Mulas JM; Millán Y; Biolatti B; Sasaki N; Nakagawa T; De Maria R
Vet J; 2012 Jan; 191(1):65-71. PubMed ID: 21282070
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
[TBL] [Abstract][Full Text] [Related]
14. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
[TBL] [Abstract][Full Text] [Related]
15. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up.
Jensen KC; Turbin DA; Leung S; Miller MA; Johnson K; Norris B; Hastie T; McKinney S; Nielsen TO; Huntsman DG; Gilks CB; West RB
Breast Cancer Res Treat; 2008 Dec; 112(3):453-9. PubMed ID: 18193353
[TBL] [Abstract][Full Text] [Related]
16. [Cloning and expression of the HER2 gene in MCF-7 cells].
Li R; Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1264-7. PubMed ID: 16234104
[TBL] [Abstract][Full Text] [Related]
17. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P
J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
Camp RL; Dolled-Filhart M; King BL; Rimm DL
Cancer Res; 2003 Apr; 63(7):1445-8. PubMed ID: 12670887
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
